Mild cognitive impairment (MCI) is not dementia. It sits in a gray zone between the normal cognitive changes of aging and the more serious decline that defines dementia. The key distinction is functional independence: people with MCI can still take care of themselves and carry out their normal daily activities, while dementia interferes with the ability to manage everyday life. That said, MCI sometimes progresses to dementia, which is why the two are so often discussed together.
How MCI Differs From Dementia
Both MCI and dementia involve measurable cognitive decline beyond what’s expected for a person’s age. But the line between them comes down to how much that decline disrupts daily functioning. Someone with MCI might forget appointments more often, lose their train of thought in conversations, or feel more overwhelmed by complex decisions. These changes are noticeable, and they show up on cognitive screening tests, but the person can still live independently.
Dementia, by contrast, means cognitive problems have become severe enough to interfere with basic responsibilities. A person with dementia may struggle to manage medications, get lost driving familiar routes, or have difficulty following a conversation. The decline is persistent and affects more than one area of thinking.
With MCI, the subtle difficulties tend to show up first in what clinicians call complex activities: managing finances, organizing work tasks, planning a multi-step project, or navigating public transportation. These tasks depend heavily on memory, attention, and executive function. Simpler daily routines like bathing, dressing, and eating remain intact. When those basic activities start to slip, the picture has usually shifted toward dementia.
Two Types of MCI
MCI is classified by which thinking skills are most affected. Amnestic MCI primarily involves memory. You might forget important information you would have easily recalled before, like recent conversations, events, or commitments. This is the type most commonly associated with eventual progression to Alzheimer’s disease.
Nonamnestic MCI affects thinking skills other than memory. It can show up as difficulty making sound decisions, misjudging the time or steps needed to complete a task, or problems with visual perception. This type may be linked to other forms of neurodegeneration, though it can also stem from treatable causes.
MCI Can Sometimes Be Reversed
One of the most important things separating MCI from dementia is that MCI is not always a one-way street. When cognitive decline stems from an underlying and treatable condition, addressing that condition can dramatically improve cognition. Common reversible causes include sleep deprivation, depression, anxiety, and medication side effects.
Not all MCI has a reversible cause, though. It can also result from early Alzheimer’s disease, stroke or other vascular disease, or traumatic brain injury. In those cases, the cognitive changes are more likely to persist or worsen. This is exactly why getting evaluated matters: figuring out what’s behind the symptoms determines whether something can be done about them.
How Often MCI Progresses to Dementia
In the general population, roughly 5% of people with MCI convert to dementia each year. That rate varies significantly based on underlying health conditions. People with essential tremor, for instance, convert at about 12% per year, nearly three times the general population rate. Parkinson’s disease carries an even higher conversion risk.
But progression is far from inevitable. Many people with MCI remain stable for years. Some even improve, particularly if the original cause was something treatable like poor sleep or depression. The overall trajectory depends on the underlying cause, other health conditions, and lifestyle factors.
MCI also becomes more common with age. At age 70, roughly 13.5% of people meet criteria for MCI. By 85, that number climbs to nearly 39%, and by 95, about half of all individuals are affected. This steep rise reflects the accumulation of vascular changes, neurodegeneration, and other age-related processes in the brain.
How MCI Is Detected
Cognitive screening tests are the primary tool for identifying MCI. The Montreal Cognitive Assessment (MoCA) is one of the most widely used. It’s a brief pen-and-paper test that evaluates memory, attention, language, and other thinking skills, scored out of 30. A score of 26 or above has traditionally been considered normal, though more recent research suggests a cutoff of 23 provides better accuracy by reducing false positives. One extra point is added for people with 12 years or fewer of formal education.
These screening tools can flag a problem, but they don’t explain the cause. A full evaluation typically includes a medical history review, blood work to check for conditions like thyroid dysfunction or vitamin deficiencies, and sometimes brain imaging. The goal is to distinguish MCI from normal aging on one end and early dementia on the other, and to identify any treatable factors driving the symptoms.
Treatment Options for MCI
There are no medications approved specifically to treat MCI on its own. However, the landscape has shifted for people whose MCI is caused by early Alzheimer’s disease. In 2024, the FDA approved a treatment (donanemab) for adults with mild cognitive impairment or mild dementia due to Alzheimer’s, provided brain imaging confirms the presence of amyloid plaques. This drug targets and clears those plaques, and it was studied specifically in people at the MCI and mild dementia stages.
For MCI not linked to Alzheimer’s, management focuses on addressing whatever is contributing to the decline. That might mean adjusting medications that cloud thinking, treating depression or anxiety, improving sleep habits, or managing cardiovascular risk factors like high blood pressure and diabetes. Regular physical exercise, social engagement, and cognitive activity are consistently associated with slower decline, though none of these is a guaranteed preventive.
Monitoring is a central part of living with MCI. Regular follow-up with cognitive testing helps track whether symptoms are stable, improving, or worsening. That ongoing picture is what guides decisions about further evaluation or treatment changes over time.